Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.

Tao X, Cai L, Chen L, Ge S, Deng X

Journal of ovarian research16 Sept 2019Cited by 42 (Europe PMC)

PMID31526389PMCIDPMC6745801DOI10.1186/s13048-019-0555-8PepBankPUB-31526389

Summary

AimsThis study was designed to evaluate the protective effects of AMPKα and SIRT1 on insulin resistance in PCOS rats, and to illuminate the underlying mechanisms.MethodsAn in vitro PCOS model was established by DHEA (6 mg/(100 g•d)), and the rats were randomly divided into the metformin group (MF group, n = 11), the exenatide group (EX group, n = 11), the PCOS group (n = 10), and the normal control group (NC group, n = 10). The MF group was administered MF 300 mg/(kg•d) daily. The EX group was subcutaneously injected EX 10μg/(kg•d) daily. After 4 weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured. Western and Real-time PCR were used to determine the expression of AMPKα and SIRT1 in the ovaries of each group.ResultsAfter 4 weeks of drug intervention, compared with untreated PCOS group, EX group and MF group had visibly decreased body weight (222.64 ± 16.57, 218.63 ± 13.18 vs 238.30 ± 12.26 g, P = 0.026), fasting blood glucose (7.71 ± 0.72, 8.17 ± 0.54 vs 8.68 ± 0.47 mmol/L, P < 0.01), HOMA-IR (8.26 ± 2.50, 7.44 ± 1.23 vs 12.66 ± 1.44, P < 0.01) and serum androgen (0.09 ± 0.03, 0.09 ± 0.03 vs 0.53 ± 0.41 ng/ml, P < 0.01) and the expressions of AMPKα and SIRT11 were increased progressively (P < 0.05).ConclusionsBoth metformin and exenatide can improve the reproductive and endocrine functions of rats with PCOS via the AMPKα-SIRT1 pathway, which may be the molecular mechanism for IR in PCOS and could possibly serve as a therapeutic target.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, exenatide reduced body weight versus untreated PCOS rats.
In plain wordsIn rats with PCOS, exenatide reduced body weight versus untreated PCOS rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
ratn = 21
DHEA-induced PCOS
Comparator
Untreated PCOS rats
Outcome group
Body weight · Metabolic and weight
Studied dose
10 μg/kg daily · subcutaneous · 4 weeksAs given in this study (rat).
Measurements
Body weight
222.64 g
exenatide
Source sentences
Summary
After 4 weeks of drug intervention, compared with untreated PCOS group, EX group and MF group had visibly decreased body weight (222.64 ± 16.57, 218.63 ± 13.18 vs 238.30 ± 12.26 g, P = 0.026)
3 context sentences(design, population, supporting numbers)
Summary · context
An in vitro PCOS model was established by DHEA (6 mg/(100 g•d)), and the rats were randomly divided into the metformin group (MF group, n = 11), the exenatide group (EX group, n = 11), the PCOS group (n = 10), and the normal control group (NC group, n = 10).
Summary · context
The EX group was subcutaneously injected EX 10μg/(kg•d) daily.
Summary · context
After 4 weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured.
Show in the study text Report a problemFND-3152638901
02AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, exenatide reduced fasting blood glucose versus untreated PCOS rats.
In plain wordsIn rats with PCOS, exenatide reduced fasting glucose versus untreated PCOS rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting blood glucose
Study
ratn = 21
DHEA-induced PCOS
Comparator
Untreated PCOS rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg/kg daily · subcutaneous · 4 weeksAs given in this study (rat).
Measurements
Fasting glucose
7.71 mmol/L
exenatide
Source sentences
Summary
fasting blood glucose (7.71 ± 0.72, 8.17 ± 0.54 vs 8.68 ± 0.47 mmol/L, P < 0.01)
3 context sentences(design, population, supporting numbers)
Summary · context
An in vitro PCOS model was established by DHEA (6 mg/(100 g•d)), and the rats were randomly divided into the metformin group (MF group, n = 11), the exenatide group (EX group, n = 11), the PCOS group (n = 10), and the normal control group (NC group, n = 10).
Summary · context
The EX group was subcutaneously injected EX 10μg/(kg•d) daily.
Summary · context
After 4 weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured.
Show in the study text Report a problemFND-3152638902
03AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, exenatide reduced HOMA-IR versus untreated PCOS rats.
In plain wordsIn rats with PCOS, exenatide reduced insulin resistance versus untreated PCOS rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHOMA-IR
Study
ratn = 21
DHEA-induced PCOS
Comparator
Untreated PCOS rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg/kg daily · subcutaneous · 4 weeksAs given in this study (rat).
Measurements
HOMA-IR
8.26 index
exenatide
Source sentences
Summary
HOMA-IR (8.26 ± 2.50, 7.44 ± 1.23 vs 12.66 ± 1.44, P < 0.01)
3 context sentences(design, population, supporting numbers)
Summary · context
An in vitro PCOS model was established by DHEA (6 mg/(100 g•d)), and the rats were randomly divided into the metformin group (MF group, n = 11), the exenatide group (EX group, n = 11), the PCOS group (n = 10), and the normal control group (NC group, n = 10).
Summary · context
The EX group was subcutaneously injected EX 10μg/(kg•d) daily.
Summary · context
After 4 weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured.
Show in the study text Report a problemFND-3152638903
04AnimalAnimal study (in vivo)Efficacy outcome
In PCOS rats, exenatide reduced serum androgen versus untreated PCOS rats.
In plain wordsIn rats with PCOS, exenatide reduced serum androgen versus untreated PCOS rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSerum androgen
Study
ratn = 21
DHEA-induced PCOS
Comparator
Untreated PCOS rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 μg/kg daily · subcutaneous · 4 weeksAs given in this study (rat).
Measurements
Serum androgen
0.09 ng/ml
exenatide
Source sentences
Summary
and serum androgen (0.09 ± 0.03, 0.09 ± 0.03 vs 0.53 ± 0.41 ng/ml, P < 0.01)
3 context sentences(design, population, supporting numbers)
Summary · context
An in vitro PCOS model was established by DHEA (6 mg/(100 g•d)), and the rats were randomly divided into the metformin group (MF group, n = 11), the exenatide group (EX group, n = 11), the PCOS group (n = 10), and the normal control group (NC group, n = 10).
Summary · context
The EX group was subcutaneously injected EX 10μg/(kg•d) daily.
Summary · context
After 4 weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured.
Show in the study text Report a problemFND-3152638904
05AnimalAnimal study (in vivo)Mechanism
In PCOS rats, exenatide increased ovarian AMPKα expression versus untreated PCOS rats.
In plain wordsIn rats with PCOS, exenatide increased ovarian AMPKα versus untreated PCOS rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAMPKα expression
Study
ratn = 21
DHEA-induced PCOS
Comparator
Untreated PCOS rats
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
10 μg/kg daily · subcutaneous · 4 weeksAs given in this study (rat).
Source sentences
Summary
and the expressions of AMPKα and SIRT11 were increased progressively (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
An in vitro PCOS model was established by DHEA (6 mg/(100 g•d)), and the rats were randomly divided into the metformin group (MF group, n = 11), the exenatide group (EX group, n = 11), the PCOS group (n = 10), and the normal control group (NC group, n = 10).
Summary · context
The EX group was subcutaneously injected EX 10μg/(kg•d) daily.
Summary · context
After 4 weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured.
Show in the study text Report a problemFND-3152638905
06AnimalAnimal study (in vivo)Mechanism
In PCOS rats, exenatide increased ovarian SIRT11 expression versus untreated PCOS rats.
In plain wordsIn rats with PCOS, exenatide increased ovarian SIRT11 versus untreated PCOS rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSIRT11 expression
Study
ratn = 21
DHEA-induced PCOS
Comparator
Untreated PCOS rats
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
10 μg/kg daily · subcutaneous · 4 weeksAs given in this study (rat).
Source sentences
Summary
and the expressions of AMPKα and SIRT11 were increased progressively (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
An in vitro PCOS model was established by DHEA (6 mg/(100 g•d)), and the rats were randomly divided into the metformin group (MF group, n = 11), the exenatide group (EX group, n = 11), the PCOS group (n = 10), and the normal control group (NC group, n = 10).
Summary · context
The EX group was subcutaneously injected EX 10μg/(kg•d) daily.
Summary · context
After 4 weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured.
Show in the study text Report a problemFND-3152638906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.

Summary

Results from this study6

Version history

Subjects

Publication types

MeSH terms

Keywords